Non‐genetic heterogeneity, altered cell fate and differentiation therapy
Open Access
- 8 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 13 (3), e12670
- https://doi.org/10.15252/emmm.202012670
Abstract
Altered capacity for self‐renewal and differentiation is a hallmark of cancer, and many tumors are composed of cells with a developmentally immature phenotype. Among the malignancies where processes that govern cell fate decisions have been studied most extensively is acute myeloid leukemia (AML), a disease characterized by the presence of large numbers of “blasts” that resemble myeloid progenitors. Classically, the defining properties of AML cells were said to be aberrant self‐renewal and a block of differentiation, and the term “differentiation therapy” was coined to describe drugs that promote the maturation of leukemic blasts. Notionally however, the simplistic view that such agents “unblock” differentiation is at odds with the cancer stem cell (CSC) hypothesis that posits that tumors are hierarchically organized and that CSCs, which underpin cancer growth, retain the capacity to progress to a developmentally more mature state. Herein, we will review recent developments that are providing unprecedented insights into non‐genetic heterogeneity both at steady state and in response to treatment, and propose a new conceptual framework for therapies that aim to alter cell fate decisions in cancer.Funding Information
- National Health and Medical Research Council (APP1182804)
- Cancer Council Victoria (APP1160018, APP1187689)
This publication has 112 references indexed in Scilit:
- Immune evasion in acute myeloid leukemia: current concepts and future directionsJournal for ImmunoTherapy of Cancer, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenanceNature Medicine, 2012
- The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaJCI Insight, 2012
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid TransformationCancer Cell, 2011
- The replication rate of human hematopoietic stem cells in vivoBlood, 2011
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997